Four-Year Survival Rate After Second Line Conversion Treatment to Hepatic Resection Using Triplet Hepatic Artery Infusion and Intravenous Cetuximab for KRAS WT Unresectable Metastatic Colorectal Cancer (European Trial Optiliv, NCT00852228)

Levi Francis1, Ducreux Michel2, Bouchahda Mohamed3, Smith Denis4, Karaboue Abdoulaye5, Hebbar Mohamed6, Lepere Celine7, Focan Christian8, Guimbaud Rosine9, Innominato Pasquale10, Carvalho Carlos11, Tumolo Salvatore12, Truant Stephanie13, Castaing Denis14, Boige Valerie15, Rougier Philippe16, Morere Jean-Francois17, Adam Rene18 INSERM UMR 776, Medical Oncology Unit, Paul Brousse Hospital, Villejuif, France Institut Gustave Roussy, Paris, France INSERM UMR 776, Medical Oncology Unit, Paul Brousse Hospital, Villejuif, France University Hospital, Bordeaux, Gironde INSERM UMR 776, Paul Brousse Hospital, Villejuif, France Medical Oncology Unit Hopital Huriez, Lille, France Hopital Europeen Georges Pompidou, Paris, France Departement d’Oncologie, CHC Clinique Saint Joseph, Liege, Belgium Service de Gastroenterologie, Hopital Rangueil, Toulouse Cedex 9, France INSERMUMR 776, Medical Oncology Unit, Paul Brousse Hospital, Villejuif, France Medical Oncology Unit, Hospital Fernando Fonseca, Amadora, Portugal UO Oncologia Azienda Ospedaliera S.Maria degli Angeli Pordenone, Pordenone, Italy Medical Oncology Unit Hopital Huriez, Lille, France Hepato-Biliary centre, Hopital Paul Brousse, Villejuif, France Institut Gustave Roussy, Villejuif, France Hopital Europeen Georges Pompidou, Paris, France Paul Brousse Hospital, Villejuif, France AP-HP Hopital Paul Brousse, Villejuif, France Introduction: Less than 15% of the patients (pts) with previously unresectable colorectal cancer (CRC) liver metastases (LM) and prior chemotherapy undergo successful complete macroscopic LM resection (R0-R1). Here, we determine Overall Survival (OS) in pts undergoing R0-R1 partial hepatectomy after second line hepatic artery infusion (HAI) with Irinotecan, 5-Fluorouracil and Oxaliplatin (IFO), and intravenous cetuximab (IV-CET) for LM-CRC in the first multicenter European trial testing this strategy.